StockIQpro
NASDAQ:TLSI

TriSalus Life Sciences, Inc.

Track all markets on TradingView
Track all markets on TradingView

TriSalus Life Sciences, Inc.'s revenue grew 53.4% in fiscal 2025 to $45.2M while operating margin rose to −59.7%, its highest in 4 years. Free cash flow was −$18.9M, −41.9% of revenue, and the diluted share count rose 49.6%.Summary generated from TriSalus Life Sciences, Inc.'s SEC filings. Latest annual report filed Mar 5, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$45.2M
Revenue growth+53.4%
Revenue, 5-yr CAGRn/a
Gross margin84.6%
Operating margin−59.7%
Net margin−86.9%
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow−$18.9M
FCF margin−41.9%
Share count change+49.6%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/a12192945
Operating income−3−36−54−36−27
Net income5−47−59−30−39
Free cash flown/a−33−51−41−19

Recent filings

From SEC EDGAR

Peers

Surgical & medical instruments & apparatus